Medication Guide App

Cleocin Phosphate Side Effects

Generic Name: clindamycin

Note: This page contains information about the side effects of clindamycin. Some of the dosage forms included on this document may not apply to the brand name Cleocin Phosphate.

Not all side effects for Cleocin Phosphate may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to clindamycin: oral capsule, oral powder for solution

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by clindamycin (the active ingredient contained in Cleocin Phosphate). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking clindamycin:

Rare
  • Cracks in the skin
  • loss of heat from the body
  • red, swollen skin scaly skin
Incidence not known
  • Abdominal or stomach cramps, pain, or tenderness
  • black, tarry stools
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • bloating
  • blood in the urine or stools
  • blurred vision
  • chest pain
  • chills
  • clay-colored stools
  • cloudy urine
  • confusion
  • cough or hoarseness
  • dark urine
  • decrease in the amount of urine
  • diarrhea
  • diarrhea, watery and severe, which may also be bloody
  • difficulty with swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • fast heartbeat
  • fever with or without chills
  • general feeling of tiredness or weakness
  • headache
  • heartburn
  • heart stops
  • hives or welts, itching, or skin rash
  • increased thirst
  • itching of the vagina or genital area
  • joint or muscle pain
  • loss of appetite
  • lower back or side pain
  • nausea or vomiting
  • no breathing
  • no pulse or blood pressure
  • pain during sexual intercourse
  • pain in the lower back or side
  • painful or difficult urination
  • pinpoint red spots on the skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rash with flat lesions or small raised lesions on the skin
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • redness of the skin
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • swollen glands
  • thick, white vaginal discharge with no odor or with a mild odor
  • thirst
  • tightness in the chest
  • unconscious
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight loss
  • vomiting of blood
  • yellow eyes or skin

For Healthcare Professionals

Applies to clindamycin: compounding powder, injectable solution, intravenous solution, oral capsule, oral powder for reconstitution

Gastrointestinal

The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment and is associated with the presence of Clostridium difficile toxin in the stool. Pseudomembranous colitis may also be associated with toxic megacolon, which can be life-threatening.

An unpleasant or metallic taste has occasionally been reported after high doses of IV clindamycin (the active ingredient contained in Cleocin Phosphate)

Common (1% to 10%): Pseudomembranous colitis, diarrhea, abdominal pain
Uncommon (0.1% to 1%): Dysgeusia, nausea, vomiting
Frequency not reported: Esophageal ulcers, esophagitis (oral preparations)

Dermatologic

Common (1% to 10%): Maculopapular rash
Uncommon (0.1% to 1%): Urticaria
Rare (less than 0.1%): Erythema multiforme, pruritus
Frequency not reported: Toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, bullous dermatitis, generalized mild to moderate morbilliform-like rash, acute generalized exanthematous pustulosis (AGEP), Sweet's Syndrome
Postmarketing reports: Serious cutaneous adverse reaction

Rash was particularly common in AIDS patients.

A 47-year-old female patient with multiple comorbidities was diagnosed with Sweet's Syndrome. The patient's symptoms developed 2 days after initiating oral clindamycin therapy for a tooth infection. The patient's symptoms persisted despite tooth extraction and continuance of antibiotic treatment with intravenous, then oral, clindamycin. Following discontinuation of clindamycin, the patient's symptoms resolved over several days. Drug-induced Sweet's syndrome was determined based on the temporal relationship of the patient's symptoms, the beginning and end of clindamycin therapy, and the exclusion of other etiologies.

Three days after starting oral clindamycin for the persistence of symptoms following a root canal, a 34-year-old male patient reported "pimples" on his scalp which changed to pustules 24 hours later. The lesions progressed and the patient's antibiotic therapy was discontinued. Two days later, the rash improved considerably. The patient met the diagnostic criteria for drug-induced Sweet's syndrome and clindamycin was the most likely cause due to the timeline of antibiotic therapy and the patient's improvement following its discontinuation.

Hypersensitivity

Frequency not reported: Anaphylactoid reactions, drug reaction with eosinophilia and systemic systems (DRESS)

Cardiovascular

Cardiorespiratory arrest and hypotension have been reported after too rapid IV administration. Thrombophlebitis has been reported after intravenous infusion.

Common (1% to 10%): Thrombophlebitis (after IV infusion)
Uncommon (0.1% to 1%): Cardiorespiratory arrest, hypotension

Genitourinary

Frequency not reported: Vaginitis

Hematologic

Neutropenia (ANC 945 cells/mm3) occurred in a 68-year-old male 6 days after receiving a single 600 mg oral dose of clindamycin (the active ingredient contained in Cleocin Phosphate) The neutrophil count normalized after 2 weeks.

Uncommon (0.1% to 1%): Eosinophilia
Frequency not reported: Neutropenia, leucopenia, agranulocytosis, thrombocytopenia

Hepatic

Common (1% to 10%): Liver function test abnormalities
Frequency not reported: Jaundice

Local

Pain, induration, and sterile abscess have been reported after intramuscular administration.

Frequency not reported: Injection site irritation, pain, abscess formation

Musculoskeletal

Frequency not reported: Polyarthritis

Renal

Frequency not reported: Renal dysfunction, as shown by azotemia, oliguria, and/or proteinuria

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)